Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

8 treatments under study, led by Qualityoflife Assessment

Related Conditions

Often studied with 10 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 2 (1)

Trial Status

Completed1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT02847559Phase 2Completed

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

NCT04278118Not ApplicableRecruiting

Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study

Showing all 2 trials

Research Network

Common Treatments

  • Qualityoflife Assessment2
  • Bevacizumab1
  • Photon Beam Radiation Therapy1
  • Hypofractionated Radiation Therapy1
  • Proton Beam Radiation Therapy1

Active Sponsors

  • National Cancer Institute (NCI)2
  • NovoCure Ltd.1
  • Northwestern University1
  • Emory University1

Top Investigators

Related Conditions

  • Grade Iii Meningioma2
  • Intracranial Neoplasm1
  • Schwannoma1
  • Supratentorial Meningioma1
  • Grade I Meningioma1

Activity Timeline